Drug Resistancy, Hiv, Virologic Failure
Conditions
Keywords
Hiv, Drug resistancy, Virologic failure, DTG-based regimen, Drug resistance mutations
Brief summary
This is a prospective observational cohort study of 2820 patients on first-line ART switching to a DTG-based first-line regimen, according to the standard of care. The study is conducted in Malawi and Zambia, in ART programs that participate in the IeDEA collaboration. Sequencing will be done on blood samples of patients with a viral load above 400 copies/mL to identify mutations.
Detailed description
Dolutegravir (DTG), a second-generation integrase strand transfer inhibitor (InSTI), is widely used in high-income countries and is recommended by the World Health Organization (WHO) as an alternative first-line ART regimen. In countries where viral load monitoring is not routinely available many patients on first-line ART will be switched to a DTG-based regimen despite the detectable viral load, which could increase the risk of selection of resistance to DTG as the majority of patients with virologic failure on first-line EFV-based ART have NRTI mutations. The investigators hypothesize that the proportion of patients experiencing virologic failure 48 and 96 weeks after switching to a DTG-based regimen will be higher in patients who switched with virologic failure (VL\>400 copies/mL) compared to patients who switched with suppressed viral replication (VL\<400 copies/mL). This is a prospective observational cohort study of 2820 patients on first-line ART switching to a DTG-based first-line regimen, according to the standard of care. The study is conducted in Malawi and Zambia, in ART programs that participate in the IeDEA collaboration. At the time of switching to DTG, a baseline study assessment will be done, and a blood sample will be taken. Sequencing will be done on blood samples of patients with a viral load above 400 copies/mL to identify mutations.
Interventions
None listed
Sponsors
University of KwaZulu
Lighthouse Trust
Centre for Infectious Disease Research in Zambia
University of Bern
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Patients * On first-line ART for 6 months or longer * Switching to any DTG-based treatment
Exclusion criteria
* No informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The proportion of patients with VF at 48 weeks between patients with and without VF at baseline. | 48 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Weight change from baseline to 48 and 96 weeks. | 48 and 96 weeks |
| Levels of adherence at baseline and after 48 and 96 weeks. | 48 and 96 weeks |
| Prevalence of neuropsychiatric symptoms at baseline, 48 weeks and 96 weeks. | 48 and 96 weeks |
| The incidence of TLD drug resistances at 48 and 96 weeks in patients with and without VF at switch. | 48 and 96 weeks |
| Prevalence of insomnia at baseline, 48 weeks and 96 weeks. | 48 and 96 weeks |
| The proportion of patients with VF at 48 weeks and 96 weeks in patients with VF at baseline who have at least one or no fully active NRTI on resistance testing. | 48 and 96 weeks |
| The proportion of patients with VF at 96 weeks between patients with and without VF at baseline. | 96 weeks |
| The number of clinical visits whilst on a DTG-based regimen up to 48 and 96 weeks. | 48 and 96 weeks |
| The number of clinical visits up to baseline, 48 and 96 weeks. | 48 and 96 weeks |
| The proportion of HIV-infected patients with VF at baseline. | Baseline |
Countries
Malawi, Zambia
Outcome results
None listed